文献速递妇科产科

子宫内膜癌微创手术患者是否需要药物性静脉血栓预防?系统综述与Meta分析

Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
PubMed 文献 · Gynecol Oncol · 2024-06-19

该系统综述与Meta分析纳入7项研究共3931例子宫内膜癌微创手术患者,评估药物性静脉血栓栓塞(VTE)预防的必要性。术后30天内,药物预防组VTE发生率为0.51%(5/990),机械预防组为0.70%(7/995),RR 1.14(95%CI 0.19-6.95),两组无显著差异;延长药物预防组VTE发生率为0.37%(4/1083),非延长药物预防组为1.14%(4/352),RR 0.41(95%CI 0.11-1.54),两组亦无显著差异。作者认为常规药物性VTE预防可能并非必要,但部分高危患者可能获益,且缺乏经过验证的风险预测模型,需进一步研究。

要点

  • 术后30天内药物预防组VTE发生率0.51%(5/990),机械预防组0.70%(7/995),RR 1.14(95%CI 0.19-6.95),无显著差异。
  • 延长药物预防组VTE发生率0.37%(4/1083),非延长药物预防组1.14%(4/352),RR 0.41(95%CI 0.11-1.54),无显著差异。
  • 作者认为常规药物性VTE预防可能并非必要,但部分高危患者可能获益,且缺乏经过验证的风险预测模型,需进一步研究。

核心结论

  • 作者认为,对于接受微创手术的子宫内膜癌患者,常规药物性VTE预防可能并非必要,因为单独机械预防似乎有效。
  • 作者指出,部分高危患者可能从药物预防或延长方案中获益,但缺乏经过验证的风险预测模型来识别此类患者,需进一步研究。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase、Cochrane Central Register of Controlled Trials、International Clinical Trials Registry Platform和ClinicalTrials.gov,检索时间从建库至2024年3月10日。
  • 共纳入7项研究,涉及3931例子宫内膜癌患者,分析使用R版本4.2.3。
  • 方案注册号:CRD 42024516595。

主要发现

  • 术后30天内,药物预防组VTE发生率为0.51%(5/990),机械预防组为0.70%(7/995),RR 1.14(95%CI 0.19-6.95),两组无显著差异。
  • 术后30天内,延长药物预防组VTE发生率为0.37%(4/1083),非延长药物预防组为1.14%(4/352),RR 0.41(95%CI 0.11-1.54),两组无显著差异。

临床怎么用

  • 作者认为,对于接受微创手术的子宫内膜癌患者,常规药物性VTE预防可能并非必要,单独机械预防似乎有效。
  • 作者指出,部分高危患者可能从药物预防或延长方案中获益,但缺乏经过验证的风险预测模型,需进一步研究。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Given the low incidence of venous thromboembolism (VTE) in endometrial cancer patients undergoing minimally invasive surgery, coupled with the existing uncertainties within guidelines regarding pharmacologic thromboprophylaxis in this area, there is an urgent need for a comprehensive literature review. This review aims to evaluate the necessity of pharmacologic VTE prophylaxis in these patients. METHODS: PubMed, Embase, Cochrane Central Register of Controlled Trials, International Clinical Trials Registry Platform, and ClinicalTrials.gov were systematically searched from inception to March 10, 2024. The analysis was performed using R version 4.2.3. RESULTS: Seven studies involving 3931 endometrial cancer patients were included in the analysis. Meta-analysis results revealed that within 30 days postoperatively, the incidence of VTE was 0.51% (5 out of 990) in the pharmacologic prophylaxis group and 0.70% (7 out of 995) in the mechanical prophylaxis group, with a relative risk (RR) of 1.14 (95% CI 0.19-6.95), indicating no significant difference between the groups. Additionally, within the same timeframe, the incidence of VTE was 0.37% (4 out of 1083) in the extended pharmacologic prophylaxis group and 1.14% (4 out of 352) in the non-extended pharmacologic prophylaxis group, yielding an RR of 0.41 (95% CI 0.11-1.54), again showing no significant difference between the groups. CONCLUSIONS: Our study indicates that routine pharmacological VTE prophylaxis may not be imperative for endometrial cancer patients undergoing minimally invasive surgery, as mechanical prophylaxis alone seems to be efficacious. However, it is crucial to acknowledge that a subset of high-risk patients may derive benefit from pharmacological prophylaxis or even extended regimens. Nonetheless, the absence of a validated risk prediction model for identifying such patients underscores the need for further research in this area. PROTOCOL REGISTRATION: CRD 42024516595.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Chen H, Chen Y, Zheng A, et al. Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis. Gynecol Oncol. 2024. PMID: 38901080. doi:10.1016/j.ygyno.2024.06.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。